
Sign up to save your podcasts
Or


In this interview, we sit down with John Tobin, Vice President of Clinical Operations at Splice Bio, to explore groundbreaking gene therapy research for Stargardt’s disease and its potential impact on the blind and visually impaired community. John shares insights into Splice Bio’s mission, how their innovative work could transform options for people living with vision loss, and what families, professionals, and supporters should know about emerging treatments. Stay tuned until the end for information on how to get involved in Splice Bio’s clinical trials. Learn more here:
www.splice.bio/clinical
Or send an email to:
#SpliceBio #genetherapy #clinicaltrials
By Sam Seavey4.9
1919 ratings
In this interview, we sit down with John Tobin, Vice President of Clinical Operations at Splice Bio, to explore groundbreaking gene therapy research for Stargardt’s disease and its potential impact on the blind and visually impaired community. John shares insights into Splice Bio’s mission, how their innovative work could transform options for people living with vision loss, and what families, professionals, and supporters should know about emerging treatments. Stay tuned until the end for information on how to get involved in Splice Bio’s clinical trials. Learn more here:
www.splice.bio/clinical
Or send an email to:
#SpliceBio #genetherapy #clinicaltrials

91,072 Listeners

43,570 Listeners

35 Listeners
16 Listeners

49 Listeners

25,812 Listeners

87,135 Listeners

24,690 Listeners

1 Listeners

28 Listeners

9,459 Listeners

1 Listeners

15 Listeners

4,514 Listeners